Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

le allowing Isis to continue to benefit as future milestones and commercial revenues are realized. By working closely with OncoGenex during the development of OGX-011, we have confidence that OncoGenex will independently maximize the value of OGX-011."

"The contributions of Isis have been instrumental in the development of OGX-011 to date and we anticipate that our positive interactions will continue with this amended relationship," added Cormack.

Under the terms of the original co-development agreement, OncoGenex paid 65% of the development costs and would receive 65% of any economic benefit resulting from the development of OGX-011. Under the terms of the amended agreement, Isis' funding commitment for 35% of the OGX-011 program ends, and OncoGenex will be responsible for all future development costs of OGX-011. These expenses have already been factored into OncoGenex' previously announced disclosures regarding anticipated development costs. Isis will receive royalties for OGX-011 ranging from 5.5% to 7% of net sales. In addition, OncoGenex will pay Isis 30% of the upfront fees and milestone payments OncoGenex receives if OncoGenex licenses OGX-011 prior to initiation of registration trials, 25% if OGX-011 is licensed before 20% of patients have been enrolled in a registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter.

OncoGenex recently announced preliminary Phase 2 data of OGX-011 in patients with hormone refractory prostate cancer at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators found that, in this patient population, OGX-011 continues to show better than expected survival results when compared to published results. OGX-011, also referred to as custirsen sodium, is a second-generation antisense oligonucleotide designed to facilitate tumor cell death induced by chemotherapy by decreasing production of clusterin, a cell survival protein linked to treatment res
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices ... has big ideas for 2014 in production and sales ... to produce high-quality, low-cost, DRM-free ebooks and to use ... , The first major development will be bookstore sales ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Robert G. Johnson, Jr. Resigns as President and ... Near-Term Commercial Opportunities, HAYWARD, Calif., Feb. 28 ... announced that Robert G. Johnson, Jr.,M.D., Ph.D., has ... a,member of Kosan,s Board of Directors. Helen S. ...
... payment, WILMINGTON, N.C., Feb. 28 PPD, ... Limited,s new drug,application (NDA) for alogliptin, a highly ... diabetes, has been accepted for filing by the ... to develop the,compound., Under PPD,s agreement with ...
... Feb. 28 The Center for Molecular,Medicine (CMM) today ... the,nation to offer a new, FDA-approved test that will ... CMM (http://www.cmmdx.org ) is offering the CellSearch(TM) System ... new tool in managing,patients with metastatic prostate cancer (MPC). ...
Cached Biology Technology:Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... serious conditions such as heart disease, epilepsy and pain, ... Unfortunately, there is still much scientists do not know ... unexpected insight into the structure of sodium channels and, ... which are responsible for ,fine-tuning, the activity of the ... edition of the Journal of Biological Chemistry . ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... nature,s repository of chemicals in plants, microbes, and marine ... be a major theme of a five-day scientific conference ... 1,200 natural products researchers from around the world. ... the City University of New York, and other New ...
... Imagine millions of cancer cells organized in thousands of small ... die, you have a candidate for a cancer drug. But ... Opinion on Drug Discovery argues that these 2D models ... effects in the body and may often give researchers misleading ...
... Fla. (July 19, 2012) A study comparing whether endothelial ... from human umbilical cord blood are more proliferative and better ... from human placenta are more vasculogenic., The study, carried out ... in a recent issue of Cell Medicine [2(3)] ...
Cached Biology News:Nature as a source of new medicines subject of ICNPR in NYC 2Nature as a source of new medicines subject of ICNPR in NYC 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells, including positive ... performance; washing, reaction and rinsing buffers for ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: